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Abstract
Background Abdominal obesity is a risk factor for Bar-
rett’s esophagus independent of GERD symptoms, but little
is understood about the biological mechanisms between
obesity and the carcinogenic pathway of esophageal
adenocarcinoma.
Aims To evaluate whether ghrelin and leptin may partially
explain the association between obesity and Barrett’s esophagus.
Methods We conducted a case–control study using
patients with a new diagnosis of Barrett’s esophagus
(cases) and two control groups frequency matched to cases
for age, gender, and geographic region: (1) patients with
gastroesophageal reflux disease (GERD) and (2) a sample
of the general population. We generated odds ratios using
logistic regressions to evaluate quartiles of serum ghrelin
or serum leptin, adjusting for known risk factors for Bar-
rett’s esophagus. We evaluated potential interaction vari-
ables using cross products and ran stratified analyses to
generate stratum-specific odds ratios.
Results A total of 886 participants were included in the
analysis. Higher ghrelin concentrations were associated with
an increased risk of Barrett’s esophagus, when compared to
the population controls, but not the GERD controls. Ghrelin
concentrations were not associated with the frequency of
GERD symptoms, but ghrelin’s relationship with Barrett’s
esophagus varied significantly with the frequency of GERD
symptoms. Leptin concentrations were positively associated
with at least weekly GERD symptoms among the population
controls and were inversely associated with Barrett’s
esophagus only among the GERD controls. Adjusting for
waist circumference did not change the main associations.
Conclusion Higher levels of ghrelin were associated with
an increased risk of Barrett’s esophagus among the general
population. In contrast, leptin was positively associated with
frequent GERD symptoms, but inversely associated with the
risk of Barrett’s esophagus among the GERD controls.
Keywords Barrett’s esophagus  GERD  Obesity 
Ghrelin  Leptin
Introduction
The incidence of esophageal adenocarcinoma has increased
dramatically over the past half century and continues to
increase, though at a slower pace [1–4]. There are several
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risk factors for esophageal adenocarcinoma, including
older age, Caucasian race, male gender, smoking tobacco,
abdominal obesity, and gastroesophageal reflux disease
(GERD) [5–8]. Perhaps the most important risk factor for
esophageal adenocarcinoma is the presence of Barrett’s
esophagus on endoscopy.
Barrett’s esophagus is a precursor lesion for esophageal
adenocarcinoma and is associated with an increased risk of
esophageal adenocarcinoma by as much as 60-fold [9]. It is
metaplasia of the lower esophagus, likely due to an aber-
rant healing process induced by esophageal injury, typi-
cally from GERD. While it is not clear why some patients
develop Barrett’s esophagus and others do not, risk factors
have been identified, such as GERD, age, gender, socioe-
conomic status, smoking tobacco, and abdominal obesity
[5, 7, 10–15]; many of these overlap the risk factors for
esophageal adenocarcinoma.
The association between abdominal obesity and Bar-
rett’s esophagus could potentially explain the increasing
incidence of esophageal adenocarcinoma [16]. Abdominal
obesity is associated with GERD, a known risk factor for
Barrett’s esophagus. Abdominal obesity is also associated
with Barrett’s esophagus, but this relationship appears to be
independent of reflux symptoms [11]. Several endogenous
compounds, including ghrelin and leptin, are associated
with obesity and may modify gastrointestinal response to
injury or function, which potentially could partially explain
the links between abdominal obesity and Barrett’s
esophagus.
Ghrelin is a peptide hormone produced by the gastric
fundus and upper gastrointestinal tract, which stimulates
appetite, promotes gastric motility, and modifies inflam-
matory pathways [17–22]. Low levels of serum ghrelin
have been found to be associated with obesity, GERD, and
Helicobacter Pylori (H. Pylori) infection [22–25]. High
levels of ghrelin are inversely associated with esophageal
adenocarcinoma [26, 27]. However, a recent study inves-
tigated the relationship between ghrelin and Barrett’s
esophagus and found a positive association with high levels
of ghrelin [28], which is difficult to reconcile with the
reported relationships between ghrelin and some of the
known risk factors for Barrett’s esophagus.
Leptin is a hormone produced by adipocytes that has a
key role in the regulation of energy balance and a large
number of other important physiological processes and is
elevated in patients with a higher body mass index (BMI),
increased body adiposity, and larger waist circumference
[23, 29]. Leptin is a pro-inflammatory peptide [30] and
stimulates growth and inhibits apoptosis in esophageal
adenocarcinoma cell lines [31, 32]. Patients with an H.
Pylori infection have lower circulating leptin concentra-
tions [24], providing, in addition to the relationship
between H. Pylori and gastroesophageal reflux [33], an
additional mechanism through which H. Pylori infection
may be protective of Barrett’s esophagus. Such evidence
suggests leptin may play a role in mediating the patho-
genesis of Barrett’s esophagus.
The aim of this study was to investigate the possible
relationships between Barrett’s esophagus and the
endogenous peptides, ghrelin, and leptin (Fig. 1), at the
time of diagnosis of Barrett’s esophagus using a case–
control study of men and women with population and
GERD control groups, and whether they potentially have a
role as biological mediators of Barrett’s esophagus with
known epidemiological risk factors.
Methods
Study Population
The study population was drawn from among 3 million
members of Kaiser Permanente Northern California
(KPNC), an integrated healthcare delivery organization.
The KPNC population closely approximates that of the
general population in the Northern California region [34].
Those selected were between ages 18 and 79, had been
members for at least 2 years prior to their index date, met
selection criteria described below, and were able to
understand written and spoken English. The KPNC Insti-
tutional Review Board approved the analyses and the study
design.
Case Definition
Potential cases included all KPNC members with a new
diagnosis of Barrett’s esophagus (to minimize selection
bias) between October 2002 and September 2005. The
index date for these cases was the date of diagnosis with
Barrett’s esophagus. These patients were identified using
ICD-9 code 530.2, which was recorded as Barrett’s
esophagus in KPNC. A board-certified gastroenterologist
Fig. 1 Possible relationships between obesity, ghrelin, leptin, gas-
troesophageal reflux disease (GERD), and Barrett’s esophagus
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(DAC) reviewed the endoscopy and pathology reports for
the potential cases. Cases with findings consistent with
recommended definitions of Barrett’s esophagus were
included: an EGD report describing a visible length of
columnar-type epithelium proximal to the gastroe-
sophageal junction/gastric folds; a biopsy of this area was
performed, and the biopsy showed intestinal-type columnar
epithelium [35]. A gastrointestinal pathologist conducted a
separate manual review of the pathology slides. Patients
were not included if they had any of the following: only
gastric-type or columnar-type metaplasia (without intesti-
nal metaplasia) of the esophagus on all pathologic evalu-
ations; no biopsy specimens of esophageal origin; biopsy
specimens of only a mildly irregular squamocolumnar
junction (i.e., irregular z-line); or a prior diagnosis of
Barrett’s esophagus.
Control Groups
Two control groups were used for this study. The first was
a GERD control group of KPNC members who had all of
the following characteristics: a GERD-related ICD-9 code
(530.11 [reflux esophagitis] or 530.81 [gastroesophageal
reflux]); a prescription sufficient for at least 90 days use of
H2RB or a PPI within the year previous to the index date;
no prior diagnosis of Barrett’s esophagus in electronic
coding; and an esophagogastroduodenoscopy (EGD) per-
formed in close proximity to the index date that did not
show esophageal columnar metaplasia of any type. A
board-certified gastroenterologist (DAC) reviewed the
EGD and pathology reports.
The second control group, the population control group,
was randomly selected from the general population within
KPNC membership using risk set sampling (this is all
people at any given point in time who are theoretically at
risk of developing Barrett’s esophagus). These patients had
no prior diagnosis of GERD or Barrett’s esophagus before
the index date. The index dates for both population and
GERD controls were determined to be the midpoint of a 2-
to 3-month selection interval for the cases. The GERD and
population controls were frequency matched to cases by
gender, age at the index date (by 5-year age groups), and
geographic region (each subject’s home medical facility).
Data Collection
All subjects completed an in-person interview related to
GERD symptoms and frequency, medical history, and use
of medications, tobacco, and alcohol; a validated food
frequency questionnaire (the Block 1998 full-length, 110
food items) [36–39]; and measurement of height, body
weight, and waist/thigh circumferences. Participants were
asked to report exposures for the year prior to the index
date. Trained interviewers completed these examinations,
most commonly at the subject’s home, using standardized
equipment. GERD symptoms were assessed using a vali-
dated symptom questionnaire and were defined as the
presence of either heartburn (a burning pain or discomfort
behind the breastbone) or acid regurgitation (a bitter- or
sour-tasting fluid coming up into the throat or mouth) [40].
Serum Measurements
Serum samples were collected from study subjects at the
time of examination and stored at -80 C for laboratory
analyses, which were performed in 2011. Plasma leptin was
measured in duplicate using a radioimmunoassay (EMD,
Millipore, St. Charles, MO) that utilized human antiserum
and 125I-peptides. The sensitivity (lower limit of detec-
tion) for the assay is 0.44 ng/mL. The mean intra- and
inter-assay coefficients of variation for the leptin assay in
Dr. Havel’s laboratory were 6.6 and 8.4 %, respectively.
Plasma ghrelin was measured in duplicate by radioim-
munoassay (Phoenix Pharmaceuticals, Inc., Belmont, CA)
using a rabbit antiserum and 125I-ghrelin as a tracer. The
sensitivity (lower limit of detection) of the assay was
45 pg/mL. The mean intra- and inter-assay coefficients of
variation for the ghrelin assay in Dr. Havel’s laboratory
were 4.3 and 12.3 %, respectively.
Statistical Analysis
We employed standard analytic techniques for an unpaired
case–control study, including unconditional logistic
regression [41–43]. Comparisons of proportions used the
binomial distribution. Analyses were performed using
STATA version 12.1 (STATA Corp, College Station, TX,
USA). The odds ratio was considered an estimate of rela-
tive risk, given the low prevalence of Barrett’s esophagus
[44]. Quartiles were generated for serum leptin and serum
ghrelin, using the distributions among the population
controls to define those quartiles. Trend analyses utilized
the p value across the categorical quartile variable. All
analyses utilizing serum leptin or serum ghrelin as a con-
tinuous variable were log-transformed to normalize the
distribution.
Based on a review of the literature, we included the
following potential confounders in the models: age, gender,
race, smoking status (never smoked, smoked in the past,
currently smoking), alcohol use (ever vs. never used), and
H. Pylori serology (serum antibody positive or negative).
In addition, the following variables were evaluated as
potential confounders and kept if inclusion in the model
changed the adjusted main effect odds ratio by 10 % or
more: education (\7, 7–9, 10–11, [11 years), waist cir-
cumference, and a comorbidity index incorporating
72 Dig Dis Sci (2016) 61:70–79
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demographic data, medical coding, and pharmacy utiliza-
tion. Using this method, we identified waist circumference
as a potential confounder.
We evaluated each of the following variables for the
presence of effect modification: race, H. Pylori serology,
frequency of GERD symptoms (no GERD symptoms or
occurring less once per week vs. at least weekly symp-
toms), BMI, and smoking status. We tested each variable
against each of the peptides in our study (ghrelin and
leptin) and against both control groups (GERD and popu-
lation). This was performed using a logistic regression that
included the outcome (cases of Barrett’s esophagus vs.
control group), the log-adjusted serum peptide levels, the
potential effect modifier, and an interaction term (the
product of the log-adjusted serum adipokine and the
potential effect modifier). Stratum-specific odds ratios were
then evaluated for each variable that had a statistically
significant interaction term (p\ 0.05).
Supplementary analyses were performed after complet-
ing the main analyses. The first of these evaluated the
effect of including waist circumference or H. Pylori
serology in the main analysis had on the odds ratio for
ghrelin and leptin. We also evaluated ghrelin and leptin for
a relationship with GERD symptoms occurring at least
weekly. We performed unconditional logistic regressions
to generate an odds ratio using quartiles of ghrelin and
leptin and frequency of GERD symptoms. The models
were adjusted for waist circumference.
Results
Patient Characteristics
A total of 953 patients were initially recruited into the
study; these included 320 cases of Barrett’s esophagus, 316
GERD controls, and 317 population controls. Of them, 886
patients had complete questionnaire and laboratory data for
all relevant variables and were included in the analysis.
The remaining 67 were excluded for missing or invalid
data for the following variables: serum leptin and ghrelin
(n = 24), waist circumference (n = 1), weight (n = 2),
race/ethnicity (n = 5), smoking status (n = 1), GERD
score (n = 1), and H. Pylori status (n = 33). The charac-
teristics of each group are summarized in Table 1. Patients
in the population controls were less likely to have at least
weekly GERD symptoms (27 %) compared to the GERD
controls (75 %) or cases of Barrett’s esophagus (80 %).
Ghrelin
Higher serum concentrations of ghrelin were positively
associated with an increased risk of Barrett’s esophagus,
when compared to the population controls (fourth quartile vs.
first quartile, adjusted odds ratio [OR] 1.87, 95 % confidence
interval [95 % CI] 1.11–3.14), with a significant test for
trend across quartiles (p = 0.05) (Table 2), although most of
the increased risk occurred between the first and second
quartiles. However, no statistically significant associations
between ghrelin and Barrett’s esophagus were seen in the
comparisons with the GERD controls (fourth quartile vs. first
quartile, OR 1.20, 95 % CI 0.73–1.98) (Table 2).
Among the population controls, the association between
ghrelin concentrations and Barrett’s esophagus varied with the
frequency of GERD symptoms (p interaction = 0.024), with
substantial differences in risk across the quartiles between
patients with versus without at least weekly GERD symptoms
(Table 3). The fourth quartile of ghrelin was associated with
an increased risk of Barrett’s esophagus among those with at
least weekly GERD symptoms (fourth vs. first quartile OR
2.48, 95 % CI 1.08–5.68), but not among those with less than
weekly or no GERD symptoms (fourth vs. first quartile OR
0.99, 95 % CI 0.30–3.22) (Table 3). In contrast, the second
and third quartiles of ghrelin were associated with Barrett’s
esophagus risk only among those with less than weekly or no
GERD symptoms (Table 3). When compared to the GERD
controls, the associations between ghrelin and Barrett’s
esophagus were similar for patients with versus without at
least weekly GERD symptoms (p interaction = 0.17)
although there were few patients among the case or GERD
controls without GERD symptoms, limiting our ability to
evaluate for interaction between these populations. We did not
observe any other interactions between ghrelin and the other
variables we tested for effect modification.
In a supplementary analysis evaluating the relationship
between ghrelin and GERD symptom frequency, we did
not find a significant relationship between ghrelin and
GERD symptoms occurring at least weekly when adjusting
for waist circumference (fourth quartile vs. first quartile
OR 1.11, 95 % CI 0.49–2.53) or when not adjusting for
waist circumference in the model (fourth quartile vs. first
quartile OR 0.70, 95 % CI 0.32–1.50).
Leptin
We found no association between levels of serum leptin
concentrations and Barrett’s esophagus for comparisons
with all the population controls (fourth vs. first quartile OR
1.49, 95 % CI 0.73–3.05); but there were significant
inverse associations among GERD controls (fourth vs. first
quartile OR 0.50, 95 % CI 0.24–1.01; p values for trend
0.04) (Table 2). We did not observe any interactions
between leptin and GERD symptoms occurring at least
weekly with the population controls (p interaction = 0.17)
or the GERD controls (p interaction = 0.24). Neither did
we observe any significant interactions between leptin and
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gender with the population controls (p interaction = 0.83)
or the GERD controls (p interaction = 0.19). No other
variables were found to interact with leptin and Barrett’s
esophagus in our evaluation of possible effect modification.
In a supplementary analysis evaluating the relationship
between leptin and GERD symptom frequency, we found
leptin was positively associated with GERD symptom
frequency among the population controls (fourth vs. first
Table 1 Patient characteristics
Cases of BE GERD controls Population controls
No. of subjects, n 300 (100 %) 296 (100 %) 290 (100 %)
Age in years, mean (SD) 62 (11) 62 (11) 62 (10)
Age, n (%)
20–39 7 (2 %) 10 (3 %) 9 (3 %)
40–59 115 (38 %) 108 (37 %) 98 (34 %)
60–79 178 (60 %) 178 (60 %) 183 (63 %)
Race, n (%)
Non-Hispanic white 263 (88 %) 240 (81 %) 247 (85 %)
Black 2 (1 %) 16 (5 %) 15 (5 %)
Hispanic 24 (8 %) 20 (7 %) 11 (4 %)
Asian 3 (1 %) 7 (2 %) 8 (3 %)
Other 8 (3 %) 13 (4 %) 9 (3 %)
Sex, n (%)
Male 218 (73 %) 204 (69 %) 198 (68 %)
Female 82 (27 %) 92 (31 %) 92 (32 %)
GERD symptom frequency, n (%)
\l/week 60 (20 %) 75 (25 %) 211 (73 %)
[or =1/week 240 (80 %) 221 (75 %) 79 (27 %)
Waist circumference in cm, mean (SD) 100.4 (14.5) 97.1 (14.3) 99.1 (16.6)
Weight in lbs, mean (SD) 190.6 (45.8) 185.2 (35.6) 192.5 (40.5)
BMI, n (%)
\19 4 (1 %) 2 (1 %) 1 (\1 %)
19–25 58 (19 %) 61 (21 %) 64 (22 %)
26–30 121 (41 %) 131 (44 %) 109 (38 %)
[30 117 (39 %) 102 (34 %) 116 (40 %)
Smoking status, n (%)
Currently smoking 39 (13 %) 29 (10 %) 31 (11 %)
Formerly smoked 161 (54 %) 145 (49 %) 127 (44 %)
Never smoked 100 (33 %) 122 (41 %) 132 (45 %)
Helicobacter pylori serology, n (%)
Negative 265 (88 %) 267 (90 %) 223 (77 %)
Positive 35 (12 %) 29 (10 %) 67 (23 %)
Serum ghrelin in pg/mL, mean (SD) 346.0 (209.4) 336.4 (194.9) 310.0 (165.8)
Quartile, mean (SD)
First quartile (\191.9 pg/mL) 158.1 (25.3) 151.3 (29.1) 154.3 (24.9)
Second quartile (191.9–269.2 pg/mL) 227.8 (22.6) 230.4 (22.6) 230.1 (21.5)
Third quartile (269.3–371.4 pg/mL) 321.2 (29.1) 317.4 (29.4) 315.1 (30.0)
Fourth quartile ([371.4 pg/mL) 569.4 (239.0) 549.7 (199.5) 542.8 (153.1)
Serum leptin in ng/mL, mean (SD) 16.15 (16.55) 16.66 (15.44) 15.62 (15.21)
Quartile, mean (SD)
First quartile (\5.97 ng/mL 4.21 (1.22) 3.67 (1.22) 4.20 (1.06)
Second quartile (5.97–10.21 ng/mL) 7.76 (1.29) 7.76 (1.14) 8.00 (1.28)
Third quartile (10.22–19.655 ng/mL) 14.46 (2.80) 13.92 (2.75) 14.01 (2.76)
Fourth quartile ([19.655 ng/mL) 36.54 (21.09) 37.87 (15.20) 36.45 (17.20)
BMI categories arc based on international standards as presented by the WHO Global Database on BMI
74 Dig Dis Sci (2016) 61:70–79
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quartile OR 3.81, 95 % CI 1.57–9.25). This relationship
was attenuated when we adjusted for waist circumference
(fourth vs. first quartile OR 2.51, 95 % CI 0.97–6.46).
Supplementary Analyses
Abdominal obesity and H. pylori are both associated with
Barrett’s esophagus and with some adipokines [5, 11, 15,
45–47]. Given these known associations, we evaluated
whether the individual inclusion/exclusion of H. pylori
infection and waist circumference influenced the associa-
tions found; if present, this which would suggest that
ghrelin and leptin may be in the biological pathway
between these factors and the risk of Barrett’s esophagus.
There was no strong evidence that ghrelin or leptin were
in the same biological pathway as H. pylori or waist
Table 2 Ghrelin, leptin, and
cases of Barrett’s esophagus
No. of case/control Crude Partially adjusteda Fully adjustedb
OR (95 % CI) OR (95 % CI) OR (95 % CI)
Ghrelin
Cases of BE versus population controls
First quartile 51/73 Ref Ref Ref
Second quartile 81/72 1.61 (0.99. 2.60) 1.54 (0.94. 2.52) 1.57 (0.96, 2.58)
Third quartile 74/73 1.45 (0.90, 2 35) 1.25 (0.76. 2.07) 1.29 (0.78, 2.14)
Fourth quartile 94/72 1.87 (1.17, 2.99) 1.77 (1.07, 2.92) 1.87 (1.11, 3.14)
p value for trend 0.02 0.07 0.05
Cases of BE versus GERD controls
First quartile 51/58 Ref Ref Ref
Second quartile 81/81 1.14 (0.70, 1.85) 1.16 (0.71, 1.90) 1.21 (0.74, 2.00)
Third quartile 74/61 1.38 (0.83, 2.29) 1.44 (0.86, 2.41) 1.55 (0.92, 2.62)
Fourth quartile 94/96 1.11 (0.69, 1.78) 1.05 (0.65, 1.72) 1.20 (0.73. 1.98
p value for trend 0.62 0.81 0.44
Leptin
Cases of BE versus population controls
First quartile 70/73 Ref Ref Ref
Second quartile 71/72 1.03 (0.65, 1.63) 0.99 (0.62, 1.60) 1.04 (0.63, 1.69)
Third quartile 82/73 1.17 (0.74, 1.85) 1.34 (0.83, 2.18) 1.47 (0.84, 2.56)
Fourth quartile 77/72 1.12 (0.70, 1.77) 1.27 (0.74, 2.19) 1.49 (0.73, 3.05)
p value for trend 0.54 0.24 0.18
Cases of BE versus GERD controls
First quartile 70/63 Ref Ref Ref
Second quartile 71/67 0.95 (0.59, 1.54) 0.98 (0.60, 1.59) 0.79 (0.47, 1.30)
Third quartile 82/88 0.84 (0.53, 1.32) 0.91 (0.56, 1.46) 0.60 (0.35, 1.04)
Fourth quartile 77/78 0.89 (0.56, 1.41) 1.01 (0.59, 1.74) 0.50 (0.24, 1.01)
p value for trend 0.52 0.93 0.04
a Adjusted for smoking status, alcohol use, H. Pylori serology, age, sex, and race
b Adjusted for waist circumference, smoking status, alcohol use, H. Pylori serology, age, sex, and race
Table 3 Ghrelin and cases of
Barrett’s esophagus by GERD
symptom frequency
Symptoms\ 1/Week Symptoms[ or =1/Week
No. of case/control OR (95 % CI) No. of case/control OR (95 % CI)
Ghrelin
Cases of BE versus. population controls
First quartile 8/53 Ref 43/20 Ref
Second quartile 21/51 3.30 (1.25, 8.68) 60/21 1.30 (0.61, 2.76)
Third quartile 24/50 3.41 (1.27, 9.15) 50/23 0.96 (0.45, 2.06)
Fourth quartile 7/57 0.99 (0.30, 3.22) 87/15 2.48 (1.08, 5.68)
Adjusted for waist circumference, smoking status, alcohol use, H. Pylori serology, age, sex, and race
Dig Dis Sci (2016) 61:70–79 75
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circumference and Barrett’s esophagus. For ghrelin, among
the population controls, the inclusion of waist circumfer-
ence in the model changed the odds ratio of the fourth
quartile versus the first quartile between ghrelin and Bar-
rett’s esophagus from 1.77 (95 % CI 1.07–2.92) to 1.87
(95 % CI 1.11–3.14) in a model containing other potential
confounders (age, sex, smoking, race, alcohol, and H.
pylori). For leptin, the inclusion of waist circumference
increased the odds ratio of the fourth quartile versus the
first quartile from 1.27 (95 % CI 0.74–2.19) to 1.49 (95 %
CI 0.73–3.05).
For ghrelin, among the population controls, the inclu-
sion of H. pylori in the model changed the odds ratio of the
fourth quartile versus the first quartile from 2.07 (95 % CI
1.24–3.44) to 1.87 (95 % CI 1.11–3.14) in a model con-
taining other potential confounders (age, sex, smoking,
race, alcohol, and waist circumference). For leptin, the
inclusion of H. pylori changed the odds ratio of the fourth
quartile versus the first quartile from 1.65 (95 % CI
0.81–3.37) to 1.49 (95 % CI 0.73–3.05).
Given the presence of associations with the population
controls, but not with the GERD controls, we evaluated
ghrelin and leptin for a possible relationship with GERD.
We did not find a significant relationship between ghrelin
and GERD symptoms occurring at least weekly (fourth
quartile vs. first quartile OR 0.70, 95 % CI 0.32–1.50),
neither was a relationship seen when adjusted for waist
circumference (fourth quartile vs. first quartile OR 1.11,
95 % CI 0.49–2.53). We found leptin was positively
associated with GERD symptom frequency among the
population controls (fourth vs. first quartile OR 3.81, 95 %
CI 1.57–9.25). When adjusted for waist circumference, this
relationship was attenuated (fourth vs. first quartile OR
2.51, 95 % CI 0.97–6.46).
Discussion
The principal goal of this study was to evaluate the rela-
tionships between ghrelin, leptin, and Barrett’s esophagus.
We did this by utilizing both population and GERD con-
trols and found that higher ghrelin levels had a positive
association with the risk of Barrett’s esophagus relative to
the population controls, but not the GERD controls. We did
not find a relationship between ghrelin and GERD in our
supplementary analysis, suggesting ghrelin’s relationship
with Barrett’s esophagus is independent of GERD. We
evaluated several variables for potential effect modification
and found GERD interacted with ghrelin in its relationship
with Barrett’s esophagus, among the highest levels of
ghrelin, though this relationship may be misleading as this
analysis was limited by the small sample size of some of
the strata. Interpretation is further limited by the
inconsistent results for the lower ghrelin levels. An inverse
association (by trend analysis) was found between leptin
and Barrett’s esophagus, but only among comparisons with
the GERD controls.
Our findings with ghrelin are contrary to what we
expected from reviewing the literature. We hypothesized
that ghrelin would have an inverse relationship with Bar-
rett’s esophagus, similar to that described in the relation-
ship between ghrelin and esophageal adenocarcinoma [26,
27]. However, Rubenstein et al. also reported a positive
association between ghrelin and Barrett’s esophagus [28]
and also demonstrated that this association was seen among
those with more frequent GERD symptoms [28].
We also aimed to determine whether the relationship
between circulating ghrelin levels and Barrett’s esophagus
might be influenced by GERD, as it is a risk factor for
Barrett’s esophagus [8, 15]. Given that some of the highest
levels of ghrelin were associated with Barrett’s esophagus
among those with more frequent symptoms in the stratified
analysis, we would have expected the same relationship
among the GERD controls, which reported more frequent
GERD symptoms than the population controls (Table 1).
Instead, we found there was no relationship when com-
pared to the GERD controls. One possibility is that ghre-
lin’s effect on Barrett’s esophagus is through its effect on
GERD, in which case we would expect a positive rela-
tionship between ghrelin and GERD. However, we found
no association between ghrelin and GERD, and Rubenstein
et al. found an inverse association [28]. Another possibility
for this inconsistency was proposed by Rubenstein et al.
that ghrelin had both a positive relationship and an inverse
relationship with Barrett’s esophagus, whereby ghrelin
may be associated with a reduced risk of GERD itself, but
an increased risk of abnormal healing of mucosal injury
into esophageal intestinal metaplasia (i.e., Barrett’s
esophagus) [28]. This might explain why we did not detect
a relationship among our GERD control group as they had
a higher frequency of GERD symptoms than the population
controls, and the protective benefits of ghrelin may have
attenuated any relationship between ghrelin and Barrett’s
esophagus not mediated by GERD, but not the absence of a
relationship between ghrelin and GERD.
The present study, which was well powered and inclu-
ded both male and female participants as well as population
and GERD controls, did not demonstrate any relationship
between leptin and Barrett’s esophagus among the popu-
lation controls, but an inverse association was seen among
the GERD controls, despite finding that leptin is positively
associated with GERD symptoms among the population
controls. This observation differs somewhat from some
studies to date [28, 48–50]. Rubenstein et al. examined the
relationship of leptin and Barrett’s esophagus in a male-
only population and found a positive relationship (third
76 Dig Dis Sci (2016) 61:70–79
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quartile vs. first quartile OR 3.25, 95 % CI 1.29–8.17) [28].
Garcia et al. also found a positive association between
leptin and Barrett’s esophagus (fifth quartile vs. first
quartile OR 8.02, 95 % CI 2.79–23.07), but they neither
controlled nor adjusted for GERD in their study design
[48]. The marked difference in our findings from these
studies could be attributed to the differences in study
population as both used a male-only population and used
cases of Barrett’s esophagus diagnosed as part of a study
protocol, although 80 out of 150 of the patients with Bar-
rett’s esophagus in Rubenstein et al. were diagnosed on a
clinically indicated esophagogastroduodenoscopy [28, 48].
We tested gender for effect modification but did not find a
significant interaction. While our study included more
females than other studies, it may have been underpowered
in the test for effect modification by gender. However,
other studies have conflicting data on how gender affects
the relationship between leptin and Barrett’s esophagus
[49, 50]. One study saw a positive relationship among its
female participants but not among the male participants nor
when the two genders were combined [49]. In contrast,
another study saw a positive association among its male
patients and an inverse association among its female
patients [50]. Given these inconsistent findings, it seems
likely that unmeasured variables that differ between patient
populations or, alternatively, differences in the collection
or assay methods for leptin, may be present in the different
studies of the relationship between leptin and Barrett’s
esophagus.
Finally, our study did not find that inclusion in the
model of abdominal obesity (as assessed by waist cir-
cumference) and, separately, H. pylori, influenced the
associations between ghrelin, leptin, and Barrett’s esoph-
agus. This suggests that abdominal obesity and H. pylori
influence Barrett’s esophagus independently of circulating
ghrelin and leptin concentrations.
This study has several strengths. First, our cases of
Barrett’s esophagus were recruited close to the time of
diagnosis, minimizing selection bias that may result from
patients modifying their behaviors after the diagnosis.
Second, we had population and GERD control groups, the
latter with a negative endoscopy for Barrett’s esophagus,
allowing us to examine the potential interactions explain-
ing why Barrett’s esophagus occurs in some patients with
GERD and not others. Third, study participants were
recruited from a population that closely parallels the gen-
eral population, making these findings easier to generalize
and less subject to selection bias. Fourth, we examined
several variables for possible interactions, which could
explain conflicting results seen in previous studies.
There are also several limitations to this study. Case–
control studies cannot establish causality, limiting the
conclusions that can be drawn from the results. The
presence of incomplete control of confounding among the
measured confounders, or the presence of unmeasured
confounders, may influence the results. Lastly, while ade-
quately powered for the main analysis, we were not ade-
quately powered to evaluate potential interactions within
the stratified analyses.
In conclusion, although there were associations between
ghrelin, leptin, and either Barrett’s esophagus or GERD
symptoms, the current data do not fully explain how
abdominal obesity increases the risk of Barrett’s esopha-
gus. Higher circulating ghrelin levels are associated with an
increased risk of Barrett’s esophagus; this association is
likely independent of GERD but may be modified by
GERD. This relationship requires further investigation as it
could partially explain the biological mechanism linking
obesity, GERD, and Barrett’s esophagus. Leptin is asso-
ciated with GERD symptoms, but is inversely associated
with Barrett’s esophagus, contrary to what has been
reported in some previous studies. These inconsistent
results highlight the need for further research into the
pathophysiology linking ghrelin, leptin and GERD, as well
as the impact of GERD treatment on these peptides. Future
studies may also benefit from the evaluation of differences
between different populations and from higher-powered
analyses of strata for risk factors of interest, including
strata of GERD symptoms and measures of obesity.
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